abstract |
The present invention involves the identification and use of compositions for treating myeloma bone disease. The compositions inhibit proteasomal activity and decrease the activity of the transcription factor NF-kappaB. Assessment of a candidate compound for its ability to inhibit production or activity of proteasomal enzymes or NF-kappaB provides a useful means to identify agents to treat myeloma bone disease. |